Monosomal Karyotype Provides Better Prognostic Prediction after Allogeneic Stem Cell Transplantation in Patients with Acute Myelogenous Leukemia

Biology of Blood and Marrow Transplantation

Volumn 17, Issue 3, 2011, Pages 356-364

  Oran, Betul ^a   Dolan, Michelle ^b   Cao, Qing ^a   Brunstein, Claudio ^a   Warlick, Erica ^a   Weisdorf, Daniel ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Acute myeloid leukemia; Cytogenetics; Hematopoietic stem cell transplantation; Monosomal karyotype

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CYTOGENETICS; CYTOMEGALOVIRUS; DISEASE FREE SURVIVAL; GENETIC ASSOCIATION; GENETIC RISK; HUMAN; KARYOTYPE; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MONOSOMY; NONMYELOABLATIVE CONDITIONING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTIVE VALUE; PROGNOSIS; RISK ASSESSMENT; SEROLOGY;

ADOLESCENT; ADULT; AGED; CHROMOSOME ABERRATIONS; COHORT STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; KARYOTYPING; LEUKEMIA, MYELOID, ACUTE; MEDICAL RECORDS; MIDDLE AGED; MONOSOMY; PROGNOSIS; RECURRENCE; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 79551681707     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2010.05.012     Document Type: Article

References (26)

1. Bloomfield C.D., Goldman A., Hassfeld D., et al. Fourth International Workshop on Chromosomes in Leukemia 1982: clinical significance of chromosomal abnormalities in acute nonlymphoblastic leukemia. Cancer Genet Cytogenet 1984, 11:332-350.
2. Arthur D.C., Berger R., Golomb H.M., et al. The clinical significance of karyotype in acute myelogenous leukemia. Cancer Genet Cytogenet 1989, 40:203-216.
3. Grimwade D., Moorman A., Hills R., et al. Impact of karyotype on treatment outcome in acute myeloid leukemia. Ann Hematol 2004, 83(Suppl 1):S45-S48.
4. Gale R.P., Horowitz M.M., Weiner R.S., et al. Impact of cytogenetic abnormalities on outcome of bone marrow transplants in acute myelogenous leukemia in first remission. Bone Marrow Transplant 1995, 16:203-208.
5. Kim D.H., Sohn S.K., Kim J.G., et al. Parameters for predicting allogeneic PBSCT outcome of acute myeloid leukemia: cytogenetics at presentation versus disease status at transplantation. Ann Hematol 2005, 84:25-32.
6. Ferrant A., Labopin M., Frassoni F., et al. Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Karyotype in acute myeloblastic leukemia: prognostic significance for bone marrow transplantation in first remission. A European Group for Blood and Marrow Transplantation study. Blood 1997, 90:2931-2938.
7. Slovak M.L., Kopecky K.J., Cassileth P.A., et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000, 96:4075-4083.
8. Grimwade D., Walker H., Oliver F., et al. Medical Research Council Adult and Children's Leukaemia Working Parties. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. Blood 1998, 92:2322-2333.
9. Byrd J.C., Mrozek K., Dodge R.K., et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002, 100:4325-4336.
10. Armand P., Kim H.T., DeAngelo D.J., et al. Impact of cytogenetics on outcome of de novo and therapy-related AML and MDS after allogeneic transplantation. Biol Blood Marrow Transplant 2007, 13:655-664.
11. Breems D.A., Van Putten W.L., De Greef G.E., et al. Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. J Clin Oncol 2008, 26:4791-4797.
12. Wagner J.E., Barker J.N., DeFor T.E., et al. Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood 2002, 100:1611-1618.
13. Barker J.N., Weisdorf D.J., DeFor T.E., et al. Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood 2005, 105:1343-1347.
14. Kern W., Haferlach T., Schnittger S., et al. Karyotype instability between diagnosis and relapse in 117 patients with acute myeloid leukemia: implications for resistance against therapy. Leukemia 2002, 16:2084-2091.
15. Estey E., Keating M.J., Pierce S., et al. Change in karyotype between diagnosis and first relapse in acute myelogenous leukemia. Leukemia 1995, 9:972-976.
16. Grimwade D., Walker H., Harrison G., et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 2001, 98:1312-1320.
17. Nevill T.J., Fung H.C., Shepherd J.D., et al. Cytogenetic abnormalities in primary myelodysplastic syndrome are highly predictive of outcome after allogeneic bone marrow transplantation. Blood 1998, 92:1910-1917.
18. Ogawa H., Ikegame K., Kawakami M., et al. Impact of cytogenetics on outcome of stem cell transplantation for acute myeloid leukemia in first remission: a large-scale retrospective analysis of data from the Japan Society for Hematopoietic Cell Transplantation. Int J Hematol 2004, 79:495-500.
19. Koreth J., Schlenk R., Kopecky K.J., et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA 2009, 301:2349-2361.
20. Tallman M.S., Dewald G.W., Gandham S., et al. Impact of cytogenetics on outcome of matched unrelated donor hematopoietic stem cell transplantation for acute myeloid leukemia in first or second complete remission. Blood 2007, 110:409-417.
21. Gorin N.C., Labopin M., Fouillard L., et al. Retrospective evaluation of autologous bone marrow transplantation vs allogeneic bone marrow transplantation from an HLA-identical related donor in acute myelocytic leukemia: a study of the European Cooperative Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 1996, 18:111-117.
22. Leopold L.H., Willemze R. The treatment of acute myeloid leukemia in first relapse: a comprehensive review of the literature. Leuk Lymphoma 2002, 43:1715-1727.
23. Stanisic S., Kalaycio M. Treatment of refractory and relapsed acute myelogenous leukemia. Expert Rev Anticancer Ther 2002, 2:287-295.
24. Wrzesien-Kus A., Robak T., Jamroziak K., et al. The treatment of acute myeloid leukemia with mitoxantrone, etoposide and low-dose cytarabine in elderly patients: a report of Polish Acute Leukemia Group (PALG) phase II study. Neoplasma 2002, 49:405-411.
25. Suciu S., Mandelli F., de Witte T., et al. Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial. Blood 2003, 102:1232-1240.
26. Schlenk R.F., Dohner K., Krauter J., et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008, 358:1909-1918.